Subscribe
shutterstock_2180131035_jhvephoto
JHVEPhoto / Shutterstock.com
8 September 2022Big PharmaStaff Writer

EU blocks $7.1bn takeover of cancer detection company

Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.
Asia
BGI wins $333m in DNA patent suit with Illumina
9 May 2022   Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.
Big Pharma
Illumina prevails against BGI at English High Court
21 January 2021   Illumina has secured a victory in its patent dispute with Chinese genome sequencing company BGI at the English High Court, which ruled that four of its patents had been infringed.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.
Asia
BGI wins $333m in DNA patent suit with Illumina
9 May 2022   Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.
Big Pharma
Illumina prevails against BGI at English High Court
21 January 2021   Illumina has secured a victory in its patent dispute with Chinese genome sequencing company BGI at the English High Court, which ruled that four of its patents had been infringed.

More on this story

Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.
Asia
BGI wins $333m in DNA patent suit with Illumina
9 May 2022   Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.
Big Pharma
Illumina prevails against BGI at English High Court
21 January 2021   Illumina has secured a victory in its patent dispute with Chinese genome sequencing company BGI at the English High Court, which ruled that four of its patents had been infringed.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB